7.5 mg tirzepatide to semaglutide conversion chart Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks Semaglutide Dosage Conversions: ml capsule size:0.25mg

7.5 mg tirzepatide to semaglutide conversion chart Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks Semaglutide Dosage Conversions: ml capsule size:0.25mg

Semaglutide Dosage Conversions: ml to mg Guide – PlexusDx

Two authors (DM and SS) independently reviewed and selected studies for inclusion and subsequently resolved discrepancies by discussion

capsule

size:0.25mg

More recently, the SYNERGY-NASH trial (published in NEJM 2024) specifically evaluated tirzepatide in patients with MASH, showing improvements in histologic endpoints